AI assistant
Immunovant, Inc. — Director's Dealing 2025
May 6, 2025
31436_dirs_2025-05-05_773fcabe-c372-4eb2-80f1-5525a9d38efb.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Immunovant, Inc. (IMVT)
CIK: 0001764013
Period of Report: 2025-05-01
Reporting Person: Girao Tiago (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-05-01 | Common Stock | A | 208388 | — | Acquired | 208388 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-05-01 | Stock Option (Right to Buy) | $15.90 | A | 293505 | Acquired | 2035-05-01 | Common Stock (293505) | Direct |
Footnotes
F1: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the total shares on April 21, 2026 and the balance will vest in twelve (12) successive substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.
F2: These options were granted pursuant to the Plan. The shares underlying the options will vest as to 25% of the total shares on April 21, 2026 and the balance will vest in twelve (12) successive substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.